Form 4: Pacira CFO Shawn Cross Granted 49,091 Restricted Stock Units

Pacira BioSciences, Inc. Chief Financial Officer Shawn Cross was granted 49,091 restricted stock units, vesting annually starting February 2027.

Summary

• Shawn Cross, Chief Financial Officer of Pacira BioSciences, Inc., acquired 49,091 shares of common stock in the form of restricted stock units.
• The transaction occurred on February 11, 2026, with a reported price of $0 per unit.
• These restricted stock units are scheduled to vest in four equal annual installments, with the first vesting date on February 15, 2027.
• Vesting is contingent upon Mr. Cross's continuous service with Pacira BioSciences, Inc. as of each vesting date.
• Following this transaction, Mr. Cross directly beneficially owns 105,341 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retaining key talent and aligning management's interests with long-term shareholder value.

Positives

• The grant of restricted stock units aligns the Chief Financial Officer's interests with the long-term performance and shareholder value of Pacira BioSciences, Inc.
• The multi-year vesting schedule incentivizes the retention of a key executive, Shawn Cross, promoting stability in leadership.

Negatives

• The restricted stock units do not provide immediate liquidity or cash flow to the executive, as they are subject to a vesting schedule.

Risks

• The vesting of the restricted stock units is contingent on Shawn Cross's continuous service with the issuer; unvested units could be forfeited if employment ceases before vesting dates.

Future Outlook

The vesting schedule for the restricted stock units extends through February 2030, indicating a long-term incentive structure designed to retain the Chief Financial Officer and align their performance with the company's future success.

Industry Context

StockSavvy.ai notes that equity grants, particularly restricted stock units with multi-year vesting, are a standard practice in the biotechnology and pharmaceutical industries to align executive incentives with long-term company performance and shareholder value, similar to practices seen at companies like Amgen or Gilead Sciences.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to a Chief Financial Officer is a common executive compensation practice across the biotechnology and pharmaceutical sectors, aligning with industry benchmarks for long-term incentive plans.
• The four-year annual vesting schedule is typical for RSU grants in the industry, comparable to structures observed at companies such as Vertex Pharmaceuticals or Regeneron Pharmaceuticals, which aim to promote executive retention and sustained performance.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with long-term company performance and value creation.
• Employees: May signal stability in executive leadership, potentially fostering a positive work environment.

Next Steps

• Continued service by Shawn Cross to ensure the vesting of restricted stock units.
• Future vesting events for the restricted stock units on an annual basis starting February 15, 2027.

Key Dates

Recommendation

This Form 4 reports a routine grant of restricted stock units to a key executive, which is a standard compensation practice. It does not provide new information that would fundamentally alter the investment thesis for Pacira BioSciences, Inc., thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Pacira BioSciences, PCRX, Shawn Cross, CFO, Restricted Stock Units, RSU, Executive Compensation, Equity Grant, Insider Transaction, Form 4